Hemophilia A and von Willebrand disease: parallel therapeutic advances in the most common inherited bleeding disorders

von Willebrand disease (VWD) and hemophilia A (HA) are the most common inherited bleeding disorders, caused by quantitative or qualitative defects of von Willebrand factor (VWF) and coagulation factor VIII (FVIII). Over the past decades, both diseases have undergone a profound therapeutic transformation, evolving from supportive care to highly effective replacement, pharmacological, and prophylactic strategies. This perspective article compares the parallel but distinct trajectories of therapeutic developments in HA and VWD, highlighting shared milestones and disease-specific limitations. In HA, advances in recombinant technology, extended half-life factor concentrates, nonfactor therapies such as FVIII mimetics and emerging gene therapy approaches have established prophylaxis as the standard of care. VWD therapy has evolved more slowly, largely owing to the marked clinical and molecular heterogeneity of this disease, that often causes difficult and delayed diagnosis. Current management is based on desmopressin, plasma-derived products, and recombinant VWF, with limited prophylaxis implementation. Nevertheless, a rapidly expanding pipeline of novel therapies -- including VWF half-life extension strategies, VWF-independent coagulation rebalancing agents, antifibrinolytics, platelet-mimetic technologies, and gene-based approaches -- suggests an imminent shift in VWD management. Collectively, these developments indicate a transition toward more individualized and mechanism-driven therapy, with the potential to fill the therapeutic gap between VWD and HA and improve long-term outcomes and quality of life in patients with these inherited bleeding disorders.